Nevertheless, results from a randomized, multicenter, placebo-controlled and dose-evaluating phase II trial, carried out on 112 biochemically recurrent prostate cancer patients, did not demonstrate a significant shortening of the PSA-doubling time in those patients that received MPX. This evidence concerns the gene KLK3 and prostate cancer.